Physician profile

James Turner

Internal Medicine · Clifton, NJ

NPI 1245424159

$6,318.89

in general payments reported to CMS, 2019-2025

24 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals Lp $1,155.95 2019-2021
Glaxosmithkline, LLC. $913.54 2019-2021
Janssen Pharmaceuticals, INC $768.29 2019-2020
Boston Scientific Corporation $620.33 2019-2021
Mannkind Corporation $525.69 2020-2021
Abbvie INC. $379.79 2019-2020
Amarin Pharma, INC. $274.95 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $269.33 2019-2022
Neurocrine Biosciences, INC. $261.52 2019
Novo Nordisk INC $248.19 2021
Lilly USA, LLC $148.92 2019-2021
Alexion Pharmaceuticals, INC. $133.33 2021
Novartis Pharmaceuticals Corporation $124.83 2019
Abiomed $100.00 2021
Teva Pharmaceuticals USA, INC. $88.07 2020-2021
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Arbor Pharmaceuticals, INC. $86.35 2019-2020
Chiesi USA, INC. $81.30 2022
Merck Sharp & Dohme LLC $29.93 2019-2020
Amgen INC. $29.34 2019-2020
Kowa Pharmaceuticals America, INC. $27.50 2021
Nabriva Therapeutics, Plc $13.99 2021
Pfizer INC. $13.21 2020
Astellas Pharma US INC $12.41 2019
Abbott Laboratories $12.13 2021

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Turner

$6,318.89

in general payments reported 2019-2025

Years
2019-2022
Top company
Astrazeneca Pharmaceuticals Lp

https://glasscript.com/doctor/193273/james-turner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.